Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Choosing to participate in an expanded access program is an important personal decision. Talk
with your doctor and family members or friends about deciding to join a research study. To
learn more about this study, please have your doctor contact the study research staff using
the Contacts provided. For general information, see the links provided in More Information.

Inclusion Criteria:

- Male or female greater than or equal to 18 years of age

- Have a diagnosis of hATTR

- Meet Karnofsky performance status and Polyneuropathy Disability (PND) score
requirements

- Have adequate complete blood counts, liver function tests and coagulation tests

Exclusion Criteria:

- Participated in an interventional hATTR amyloidosis clinical trial involving RNA
interference (RNAi) therapeutics within the last 12 months

- Are currently eligible to participate in or currently enrolled in an ongoing
interventional hATTR amyloidosis clinical trial

- Have inadequate cardiac function

- Known primary amyloidosis (AL amyloidosis) or leptomeningeal amyloidosis

- Have known serious comorbidities or considered unfit for the program by the
investigator

- Prior or planned liver or heart transplantation